Navigation Links
Halozyme Therapeutics Announces Data From Two Phase 1 Studies of PEGPH20 Demonstrating Targeting of Hyaluronan in Tumor Stroma
Date:10/27/2011

phy (FDG-PET) imaging showed a reduction in metabolic activity of lung metastases in a patient with metastatic rectal carcinoma after PEGPH20 treatment.

The expected mechanism of action of PEGPH20 was further confirmed by histochemical analysis of pre- and post-treatment tumor biopsies. Biopsies of liver metastases from two patients with colorectal carcinoma were stained for HA before and after one cycle of treatment with PEGPH20.  Reduced HA staining was observed in biopsies from both patients after treatment.

"We are pleased with the results from these translational studies which provide further support to the hypothesis that PEGPH20 can favorably alter the tumor stroma of HA rich tumors," said Joy Zhu, MD, PhD, Vice President of Oncology Clinical Development at Halozyme.  "The degradation of the protective halo of HA and normalized tumor perfusion are promising results that support our ongoing clinical trial studying PEGPH20 in combination with gemcitabine in patients with pancreatic cancer."

A copy of the poster may be obtained on the company website.

About Halozyme

Halozyme Therapeutics is a biopharmaceutical company developing and commercializing products targeting the extracellular matrix for the insulin, cancer, dermatology and drug delivery markets. The company's product portfolio is based primarily on intellectual property covering the family of human enzymes known as hyaluronidases and additional enzymes that affect the extracellular matrix. Halozyme's Enhanze™ technology is a novel drug delivery platform designed to increase the absorption and dispersion of biologics. The company has key partnerships with Roche, Baxter, ViroPharma and Intrexon to apply Enhanze™ technology to therapeutic biologics including Herceptin®, MabThera®, immunoglobulin, Cinryze® and recombinant human alpha 1-antitrypsin. Halozyme's Ultrafast Insulin program combines its rHuPH20 enzyme with mealt
'/>"/>

SOURCE Halozyme Therapeutics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Halozyme Begins Clinical Trial with HTI-501 in Women with Edematous Fibrosclerotic Panniculopathy
2. Halozyme Therapeutics to Present at the JMP Securities Healthcare Conference on September 28
3. Halozyme Therapeutics to Present Data on its Ultrafast Insulin Programs at the Upcoming American Diabetes Association 71st Scientific Sessions
4. Halozyme Therapeutics to Present at the Jefferies 2011 Global Healthcare Conference on June 9
5. Halozyme Therapeutics Reports First Quarter 2011 Financial Results
6. Halozymes Ultrafast Insulin Generates Faster-In and Faster-Out Profile for Type 1 Diabetes Patients Using Insulin Pumps
7. Halozyme Announces Roche Doses First Patient in Phase 3 Clinical Trial With Subcutaneous MabThera® (rituximab)
8. Halozyme Therapeutics Reports Third Quarter 2010 Financial Results
9. Halozyme Receives $5.5 Million Payment From Baxter
10. Halozyme Therapeutics Reports 2008 Third Quarter Financial Results
11. Halozyme Therapeutics Begins Phase 2 Clinical Trial of Insulin With rHuPH20 in Type 1 Diabetic Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/4/2015)... --  Intrexon Corporation (NYSE: XON ) today ... after the market closes on May 11, 2015.  The ... 5:30 PM ET to discuss the results and provide ... may be accessed by dialing 1-888-346-3959 (Domestic US) and ... Call."  Participants may also access the live webcast through ...
(Date:5/1/2015)... 2015 /PRNewswire/ - BioAmber Inc. (NYSE: BIOA ), ... it has priced an underwritten registered offering of 3,900,000 ... $9.00 per share, and granted the underwriters in the ... additional 585,000 shares of its common stock. The gross ... is expected to close on May 6, 2015, subject ...
(Date:5/1/2015)... -- Albany Molecular Research Inc. (NASDAQ: AMRI ) ... President and Chief Executive Officer, will present at the ... on Wednesday, May 13, 2015 at 4:20 p.m. ET. ... can be accessed at AMRI,s Investor Relations web site at ... be archived for 90 days following the live presentation. ...
(Date:4/30/2015)...   Tamir Biotechnology , a leading developer of ... Ebola antiviral therapy program. Clinical Progress ... being evaluated and considered by a number of clinicians ... the first quarter of 2015, the company participated in ... Evaluation of Potential Treatments and Vaccines For Ebola In ...
Breaking Biology Technology:Intrexon to Announce First Quarter 2015 Financial Results on Monday, May 11, 2015 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 2BioAmber Inc. Announces Pricing Of $35.1 Million Registered Offering 3AMRI to Present at the Bank of America Merrill Lynch 2015 Health Care Conference 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 2Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 3Tamir Biotechnology Provides Update on TMR004 Development Against Mutating Ebola 4
... Oct. 2 454 Life Sciences, a Roche,company, ... to,conduct large scale genetic re-sequencing in hundreds of ... responses to a widely,prescribed class of drug. The ... sufficient genetic variation can be identified and,validated to ...
... SAFC(R), a member of the,Sigma-Aldrich(TM) Group ... plans to begin,construction of a new cGMP ... its Pharma sector,s St. Louis manufacturing campus.,This ... substance requirements,that demand a combination of small ...
... China, Oct. 2 HUYA Bioscience,International (HUYA), ... development of key disease-fighting drugs sourced from ... novel clinical stage anti-arrhythmic,compound from the prestigious ... of Sciences. The compound, HBI-3000 or ...
Cached Biology Technology:New Pharmacogenomic Approach: 454 Life Sciences and Perlegen to Collaborate in Drug Response Sequencing Study 2New Pharmacogenomic Approach: 454 Life Sciences and Perlegen to Collaborate in Drug Response Sequencing Study 3SAFC Supports Potent API Conjugate Manufacturing With New St. Louis Production Suite 2SAFC Supports Potent API Conjugate Manufacturing With New St. Louis Production Suite 3HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica 2HUYA Bioscience International Licenses Clinical Stage Anti-Arrhythmic Compound from the Shanghai Institute of Materia Medica 3
(Date:4/1/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces the second shipment ... underway to early access pre-order customers. ... retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop ... accepted at all outlets and very easy to use. ...
(Date:3/30/2015)... 26, 2015 Research and Markets ( ... "Global Gesture Recognition Market in Automotive Sector 2014-2018" ... the Global Gesture Recognition market in Automotive Sector to ... 2013-2018. Gesture recognition is the ability of ... of an individual. Gesture recognition technology can be 2D-based ...
(Date:3/24/2015)... March 24, 2015   NexID Biometrics LLC, ... security-authentication needs, today announced the beginning of shipments of ... The company, based in Potsdam, ... three-day Connect:ID Expo, which began here today at the ... version 2.0 of its SDK boosts the accuracy rate ...
Breaking Biology News(10 mins):NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2NexID Begins Shipments Of Version 2.0 Fake-Finger-Detection Solution 2
... Science (via Science Express http://www.sciencexpress.org) on July 28th reveals ... in the open ocean ?the largest and least known ... climate change and fishing over the past 50 years, ... highlight a surprising global pattern of open ocean hotspots ...
... gene expression can influence the fates of cells ... than previously thought, according to new research from ... University of California, Berkeley. By combining experimental and ... found evidence that the virus may become latent ...
... has broken the immune system's code, report researchers from ... when its host is most vulnerable and to launch ... defenses. , In the 29 July 2005 issue of ... interferon-gamma, a chemical messenger the immune system uses to ...
Cached Biology News:Scientists discover global pattern of big fish diversity in open oceans 2Scientists discover global pattern of big fish diversity in open oceans 3Scientists discover global pattern of big fish diversity in open oceans 4Scientists discover global pattern of big fish diversity in open oceans 5Random gene expression may drive HIV into hiding 2Random gene expression may drive HIV into hiding 3Random gene expression may drive HIV into hiding 4Immune system's distress signal tells bacteria when to strike back 2Immune system's distress signal tells bacteria when to strike back 3